shadow_tr

The People of Tulane Cancer Center Research


William William "Rusty" Robinson, III, M.D.
Maxwell E. Lapham Professor of Gynecologic Oncology Section Chief, Gynecologic Oncology Tulane Cancer Center Program Member in the Clinical & Translational Research Program

Contact Information
Email: wrobinso@tulane.edu
Phone: 504-988-5217
Address: 1430 Tulane Ave., Box SL-11, New Orleans, LA 70112-2699

Biographical Narrative
Dr. Robinson is board-certified in gynecologic oncology, having completed residency training at Tulane University Medical School in 1989 and a fellowship at the University of Southern California in 1992. He served as faculty at Tulane University from 1992 to 1999, and then was in a combined academic/private practice in Amarillo, Texas from 1990 to 2010. He has returned to New Orleans to help rebuild the community and improve the care of women with cancer. He has written over 50 scientific publications and held multiple professional leadership roles, including serving as president of the Western Association of Gynecologic Oncologists, chair of the Chemoprevention Subcommittee of the Gynecologic Oncology Group and vice-chair of the Coding Committee of the Society of Gynecologic Oncologists. His research interests include intraperitoneal chemotherapy and immunotherapy for Ovarian Cancer, gynecologic cancer prevention and control, and HIV-related malignancies in women.

Selected Publications

INTRAPERITONEAL CHEMOTHERAPY FOR OVARIAN CANCER

Tiersten A, Liu PY, Smith H, Wilczynski S, Robinson WR, Markman M, Alberts D. Chemotherapy Resistance as a Predictor of Progression-Free Survival in Ovarian Cancer Patients treated with Neoadjuvant Chemotherapy and Surgical Cytoreduction Followed by Intraperitoneal Chemotherapy: A Southwest Oncology Group Study. Oncology 77(6):395-399, 2010.

Robinson WR, Beyer J. Factors affecting the completion of intraperitoneal chemotherapy for ovarian cancer. Int J Gynecol Oncol. 20(1): 70-74, 2010.

Tiersten A, Liu PY, Smith H, Wilczynski S, Robinson WR, Markman M, Alberts D. Phase II Evaluation of Neoadjuvant Chemotherapy and Debulking Followed by Intraperitoneal Chemotherapy in Women with Stage III and IV Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer: Southwest Oncology Group Study S0009. Gynecol Oncol 111(3): 444-449, 2009.

Markman M, Smith Ho, Moon J, Wilczynski S, Tiersten AD, Hannigan EV, Robinson WR, Rivkin SE, Anderson GL, Liu PY. Southwest Oncology Group Trial S9912: Inrtraperitoneal Cisplatin and Paclitaxel plus Intravenous Paclitaxel and Pegylated Liposomal Doxyrubicin as Primary Chemotherapy of Small-Volume Residual Stage III Ovarian Cancer. Gynecol Oncol. 114(2):206-209, 2009.

IMMUNOTHERAPY OF OVARIAN CANCER

Wright SE, Rewers-Felkins KA, Quinlin IS, Fogler WE, Phillips CA, Townsend M, Robinson W, Philip R. MHC-unrestricted lysis of MUC1-expressing cells by human peripheral blood mononuclear cells. Immun Invest. 37:215-225, 2008

.

Dadabayev AR, Wang Z, Zhang Y, Zhang J, Robinson WR, Lim SH. Cancer Immunotherapy Targeting Sp17: When should the Laboratory Findings Be Translated to the Clinics? Am J Hemat. 80:6-11; 2005.

Robinson W, Adams J, O’Quinn AG, Freeman S. Vaccine therapy for ovarian cancer using Herpes Simplex Virus Thymidine Kinase (HSV-TK) suicide gene transfer technique: A Phase I Trial. Gene Ther Molec Biol. 2: 31-40, 1998.

HIV-RELATED MALIGNANCIES IN WOMEN

W. Robinson, Diagnosis and management of cervical neoplasia in UpToDate, ed. Rose BD. UpToDate, Wellesley, MA, 2000-11-.

W. Robinson. Diagnosis and Management of Vulvar/vaginal dysplasia in HIV-infected women. In UpToDate ed. Rose BD. UpToDate, Wellesley, MA 2009-11-.

 

1430 Tulane Ave, New Orleans, LA 70112 504-988-5187 medsch@tulane.edu